Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 17/20 | 0.44 |
| ▸ | CASP1 | P29466 | 16/20 | 0.44 |
| ▸ | CASP7 | P55210 | 16/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 15/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.44 |
| ▸ | USP2 | O75604 | 13/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380330 | 0.95 | CYP1A2 (0.41) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL8226859 | 0.86 | RPS6KB2 (0.50) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL7907910 | 0.82 | CYP1A2 (0.41) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL8381126 | 0.81 | CYP1A2 (0.47) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL15958616 | 0.81 | RPS6KB2 (0.47) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL8383323 | 0.80 | ADORA2A (0.40) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL8380271 | 0.80 | RPS6KB2 (0.49) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL13595005 | 0.78 | RPS6KB2 (0.46) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL7907933 | 0.78 | ALDH1A1 (0.39) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL8381299 | 0.78 | ALDH1A1 (0.38) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | CYP1A2 437/4885CASP1 147/4885CASP7 480/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | CYP1A2 467/4885CASP1 171/4885CASP7 702/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | CYP1A2 467/4885CASP1 171/4885CASP7 702/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | CYP1A2 685/4885CASP1 341/4885CASP7 1352/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | CYP1A2 628/4885CASP1 301/4885CASP7 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.